Correction: Supplementary drug treatment to reduce weight in adolescents with severe obesity.

Johannes Rolin,Rønnaug Astri Ødegård,Viktoria Vedeler Amundsen,Unni Mette Stamnes Köpp,Ane Kokkvoll,Pétur Benedikt Júlíusson,Jøran Hjelmesæth

Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke（2023）

引用 0|浏览8

暂无评分

摘要

In 2021, the Norwegian Medicines Agency approved the use of daily injection of liraglutide 3.0 mg (Saxenda) as a supplement to lifestyle treatment for weight control in children ≥ 12 years of age with obesity (isoBMI ≥ 30). We share the treatment experiences of six multidisciplinary obesity clinics in the specialist health service.

查看译文

关键词

severe obesity,supplementary drug treatment,adolescents

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要